KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Current Assets (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Current Assets data on record, last reported at $375.1 million in Q4 2025.

  • For Q4 2025, Current Assets fell 24.34% year-over-year to $375.1 million; the TTM value through Dec 2025 reached $375.1 million, down 24.34%, while the annual FY2025 figure was $375.1 million, 24.34% down from the prior year.
  • Current Assets reached $375.1 million in Q4 2025 per PACB's latest filing, down from $394.2 million in the prior quarter.
  • Across five years, Current Assets topped out at $1.2 billion in Q1 2021 and bottomed at $375.1 million in Q4 2025.
  • Average Current Assets over 5 years is $796.8 million, with a median of $867.2 million recorded in 2022.
  • Peak YoY movement for Current Assets: surged 687.83% in 2021, then crashed 34.28% in 2025.
  • A 5-year view of Current Assets shows it stood at $1.1 billion in 2021, then dropped by 22.62% to $852.1 million in 2022, then fell by 12.91% to $742.0 million in 2023, then crashed by 33.2% to $495.7 million in 2024, then fell by 24.34% to $375.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $375.1 million in Q4 2025, $394.2 million in Q3 2025, and $413.4 million in Q2 2025.